At a glance
ClinicalIndex Comparison Record- ✓Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology
- ✓Age ≥18 years old
- ✓Signed informed consent
- ✓Eligible to receive fluzoparib monotherapy or combination therapy per investigator
- ✕Pregnant or lactating women
- ✕Participating in other research with intervention measures outside routine clinical practice
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
In Brief
An observational study evaluating fluzoparib monotherapy or combination therapy for Ovarian Cancer. Currently recruiting, targeting 490 participants across 1 site.
Detailed Summary
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.
Study Details
Timeline
Interventions
patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy